Former Trump White House adviser Stephen Miller claimed on Friday that drug companies would have already modified the formulations of COVID-19 vaccines to block the new Omron version if Donald Trump remains president.
Speaking on the special edition of Fox News’ Hannity, Mr Miller told the audience that if Mr Trump were still in office the US would have “already modified vaccines to deal with the new variants”.
“President Trump brought vaccines to us in record time … and he will have updates as well,” he said.
Mr Miller did not explain how the former president would have enabled vaccine makers to develop vaccines before new variants were discovered and their genetic sequences mapped by virologists.
In January 2020, just 10 days after the first case was reported in China’s Wuhan province, scientists were able to sequence the genetic code of SARS-CoV-2 – the virus that causes COVID-19.
But it was not until nearly a year later, on 14 December 2020, when the first COVID-19 vaccination outside of clinical trials in the US was given to New York City intensive care unit nurse Sandra Lindsay.
Development of an updated vaccine designed for newer variants, such as the Omicron variant, which recently emerged in South Africa, will not take nearly as long, but it is not clear whether the President will be able to develop, manufacture, and develop any Test new vaccine candidates.
In a June press conference with President Joe Biden, Pfizer CEO Albert Boerla said his company could produce a modified COVID-19 vaccine for use within 100 days of the identification of a new “escape variant” that would replace existing ones. Vaccines can be avoided.
Vaccines such as Pfizer and Moderna use messenger RNA technology that can be quickly adapted to create vaccines for new variants.
Last month, Jacqueline Miller, Moderna’s senior vice president and head of infectious disease research, told Nature that his company was submitting test cases to the Food and Drug Administration to “establish a process” by using vaccines developed to block beta and delta variants of SARS-CoV-2, by which new type-specific vaccines Can hit the streets fast.
“If there is another strain that develops those mutations in the future, we can take advantage of what we already learned from studying the beta version,” she said.
Credit: www.independent.co.uk / Stephen Miller